MMD Secures Funding to Reshape $3B Aneurysm Repair Market

NEW YORK, NY – January 09, 2026 – Major Medical Devices, Inc. (MMD), a medical technology innovator, has secured a strategic funding partnership with TCA Venture Group to advance a novel device poised to disrupt the treatment of abdominal aortic aneurysms (AAA). The investment will accelerate the development of a next-generation system designed to overcome critical limitations of current therapies, potentially transforming a market valued at over $3 billion annually.

The collaboration provides MMD with the capital and strategic support needed to complete first-in-human clinical studies and navigate the regulatory landscape, bringing its unique endovascular aneurysm repair (EVAR) device closer to commercial reality.

"We are excited to partner with TCA, an organization that shares our commitment to transforming the treatment of AAAs," said Charles Kerr, President of MMD, in a statement. "This partnership marks a significant step forward in bringing our innovative AAA solution to patients who need better and more adaptable treatment options."

Addressing Unmet Needs in a Growing Market

Abdominal aortic aneurysms, a life-threatening bulge in the body's main artery, represent a significant and growing health concern, particularly within the aging global population. The global market for EVAR, the minimally invasive standard of care, was valued at over $2.6 billion in 2020 and is projected to exceed $4.3 billion by 2030. While EVAR offers substantial benefits over traditional open surgery, including shorter recovery times, it is not without its challenges.

Current EVAR systems are plagued by limitations that exclude a significant portion of patients and can lead to costly post-procedure complications. A primary issue is anatomical constraints; devices often require specific aortic and iliac artery dimensions, which a notable number of patients, particularly women, do not possess. Furthermore, the standard transfemoral (groin) access can lead to complications like bleeding, hematomas, and vessel damage.

Perhaps the most persistent challenge is the incidence of "endoleaks," where blood continues to flow into the aneurysm sac after the stent graft is placed. This complication often necessitates lifelong surveillance and a high rate of secondary interventions, diminishing the long-term cost-effectiveness and durability of the repair. MMD's technology aims to directly address these well-documented unmet needs.

A New Angle of Attack: The Promise of Upper Extremity Access

The core innovation of MMD's device lies in its design, which enables upper extremity (arm) access and features a lower profile. This represents a paradigm shift from the conventional transfemoral approach and could be a game-changer for both surgeons and patients. The concept of using arm arteries, like the radial artery in the wrist, is not new to vascular medicine; it has become the gold standard in many interventional cardiology procedures due to its superior safety profile.

Studies in coronary interventions have shown that radial access can reduce major bleeding events and access-site complications by over 70% compared to femoral access. Patients also benefit from greater comfort and can often walk almost immediately after the procedure, leading to faster recovery and shorter hospital stays.

By being the first to integrate this capability into an EVAR system, MMD could unlock these benefits for AAA patients. "Enabling upper-extremity access is a logical and meaningful step forward – one that has benefited many other vascular procedures," stated Dr. Anahita Dua, Chief Medical Officer of Major Medical Devices. "We're proud to be the first to bring this capability to EVAR, and even more proud of the impact it can have on patient care, which remains our highest priority."

This approach would immediately expand the treatable patient population to include those with severe peripheral artery disease or complex anatomy in their leg arteries, who are currently poor candidates for traditional EVAR. Combined with a lower-profile design for navigating smaller, more tortuous vessels, the system promises improved procedural control and adaptability for surgeons tackling complex cases.

Strategic Backing from a Venture Powerhouse

The partnership with TCA Venture Group is more than just a financial transaction; it is a significant vote of confidence from one of the nation's most active and experienced angel investor networks. Founded in 1997, TCA has a formidable track record, having invested over $300 million in more than 560 companies, which have gone on to attract an additional $2.2 billion in follow-on capital.

With a portfolio that has yielded an impressive 25% internal rate of return (IRR) and over 100 successful exits, TCA is known for its rigorous due diligence and strategic support. The group's focus on life sciences, which comprised over half of its investment activity in 2023, makes its backing of MMD particularly noteworthy.

"We're excited by this investment because we believe MMD can transform the EVAR space with a solution that's clinically safer, easier to deploy and more cost-effective than current standards," commented Steven Liu, MD, of Tech Coast Venture Group. "They have an exceptional team supported by some of the best advisory and key opinion leaders we've seen. Several specialities have already made similar upper-approach transitions and MMD is now positioned to bring that advantage to aortic and iliac endovascular repair."

TCA's involvement provides MMD not only with capital but also with mentorship and access to a vast network of industry experts, which will be invaluable as the company navigates the next critical phases of development.

The Rigorous Path to Market Disruption

Despite the promising technology and strong financial backing, the road ahead for Major Medical Devices is both challenging and clearly defined. As a permanently implanted, life-sustaining product, the AAA repair device is classified as a Class III medical device by the U.S. Food and Drug Administration (FDA), subjecting it to the most stringent regulatory pathway.

The journey from its current stage to market approval involves several resource-intensive steps. Following encouraging preclinical data, the company will now focus on initiating its first-in-human (FIH) feasibility studies under an Investigational Device Exemption (IDE). Success in these early trials will pave the way for larger, pivotal clinical trials designed to definitively prove the device's safety and effectiveness compared to existing treatments. This entire clinical evaluation process can span several years and requires significant investment.

Once sufficient data is collected, MMD will submit a Premarket Approval (PMA) application to the FDA, a comprehensive process that itself can take one to two years to review. Throughout this journey, MMD will be entering a competitive arena dominated by industry giants like Medtronic, W. L. Gore & Associates, and Cook Medical. These established players have deep market penetration and extensive long-term clinical data supporting their products. To succeed, MMD must not only demonstrate superior clinical outcomes but also effectively communicate its value proposition to physicians and healthcare systems, proving that its innovative approach warrants a shift in surgical practice. The new funding and strategic partnership are the crucial first steps in tackling that challenge head-on.